Northpointe Capital LLC lifted its position in shares of Merck & Company, Inc. (NYSE:MRK) by 73.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 124,159 shares of the company’s stock after purchasing an additional 52,597 shares during the quarter. Northpointe Capital LLC’s holdings in Merck & were worth $7,957,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in MRK. Mycio Wealth Partners LLC raised its position in shares of Merck & by 20.9% during the 1st quarter. Mycio Wealth Partners LLC now owns 20,235 shares of the company’s stock valued at $1,286,000 after acquiring an additional 3,495 shares in the last quarter. Cubic Asset Management LLC grew its stake in Merck & by 2.3% during the 1st quarter. Cubic Asset Management LLC now owns 13,250 shares of the company’s stock worth $842,000 after buying an additional 300 shares during the last quarter. Dubuque Bank & Trust Co. grew its stake in Merck & by 19.9% during the 1st quarter. Dubuque Bank & Trust Co. now owns 47,488 shares of the company’s stock worth $3,017,000 after buying an additional 7,892 shares during the last quarter. Delta Asset Management LLC TN grew its stake in Merck & by 2.6% during the 1st quarter. Delta Asset Management LLC TN now owns 12,499 shares of the company’s stock worth $794,000 after buying an additional 316 shares during the last quarter. Finally, Duncker Streett & Co. Inc. grew its stake in shares of Merck & by 6.1% in the first quarter. Duncker Streett & Co. Inc. now owns 53,537 shares of the company’s stock worth $3,402,000 after purchasing an additional 3,091 shares in the last quarter. 73.15% of the stock is currently owned by hedge funds and other institutional investors.
In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.25% of the company’s stock.
Merck & Company, Inc. (MRK) opened at $55.48 on Monday. The company has a market capitalization of $151,151.77, a P/E ratio of 14.26, a PEG ratio of 2.39 and a beta of 0.78. Merck & Company, Inc. has a 12-month low of $54.41 and a 12-month high of $66.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.
Merck & (NYSE:MRK) last released its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The company’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.07 earnings per share. sell-side analysts expect that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Merck & Company, Inc. (NYSE:MRK) Stake Boosted by Northpointe Capital LLC” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/11/13/northpointe-capital-llc-purchases-52597-shares-of-merck-company-inc-mrk.html.
MRK has been the subject of several research analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $73.00 price objective (down from $74.00) on shares of Merck & in a research note on Monday, July 24th. BidaskClub lowered Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Morgan Stanley lowered Merck & from an “overweight” rating to an “equal weight” rating and set a $56.00 target price on the stock. in a research report on Monday, October 30th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $74.00 target price (down from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Finally, UBS AG lowered their price objective on Merck & from $72.00 to $67.00 and set a “buy” rating on the stock in a report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Merck & has an average rating of “Hold” and a consensus price target of $67.07.
Merck & Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.